Table 1.
Description of study participant characteristics at baseline, overall and by sexa
| n (%) | ||||
|---|---|---|---|---|
| Characteristic | Overall (N=766) |
Men (N=402) |
Women (N=364) |
p-value |
| Infection type | 0.88 | |||
| Incident only | 152 (19.8) | 77 (19.2) | 75 (20.6) | |
| Any prevalent | 307 (40.1) | 163 (40.5) | 144 (39.6) | |
| None | 307 (40.1) | 162 (40.3) | 145 (39.8) | |
| Age (years) | <0.0001 | |||
| <45 | 200 (26.1) | 58 (14.5) | 142 (39.0) | |
| 45-54 | 328 (42.9) | 171 (42.6) | 157 (43.1) | |
| ≥55 | 238 (31.1) | 173 (43.0) | 65 (17.9) | |
| Race/Ethnicity | <0.0001 | |||
| White, non-Hispanic | 254 (33.2) | 238 (59.2) | 16 (4.4) | |
| Black, non-Hispanic | 413 (53.9) | 144 (35.8) | 269 (73.9) | |
| Other race or Hispanic | 99 (12.9) | 20 (5.0) | 79 (21.7) | |
| Study site | ||||
| Baltimore, Maryland | 140 (18.3) | 140 (34.8) | NA | |
| Bronx, New York | 116 (15.1) | NA | 116 (31.9) | |
| Brooklyn, New York | 134 (17.5) | NA | 134 (36.8) | |
| Chicago, Illinois | 253 (33.0) | 139 (34.6) | 114 (31.3) | |
| Pittsburgh, Pennsylvania | 123 (16.1) | 123 (30.6) | NA | |
| HIV status | 0.02 | |||
| Uninfected | 197 (25.7) | 117 (29.1) | 80 (22.0) | |
| Infected | 569 (74.3) | 285 (70.9) | 284 (78.0) | |
| Current CD4 T cell count (cells/μL) | 0.17 | |||
| ≥500 | 313 (55.0) | 165 (57.9) | 148 (52.1) | |
| <500 | 256 (45.0) | 120 (42.1) | 136 (47.9) | |
|
Current HIV RNA viral load
(copies/mL) |
<0.0001 | |||
| <200 | 415 (73.3) | 228 (80.9) | 187 (66.5) | |
| 200-19,999 | 94 (16.7) | 32 (11.3) | 62 (22.1) | |
| ≥20,000 | 54 (9.6) | 22 (7.8) | 32 (11.4) | |
| Current ART use | 0.43 | |||
| No | 101 (17.8) | 47 (16.5) | 54 (19.0) | |
| Yes | 468 (82.2) | 238 (83.5) | 230 (81.0) | |
| Smoked cigarettes in the last 6 months | <0.0001 | |||
| No | 439 (57.8) | 271 (68.3) | 168 (46.3) | |
| Yes | 321 (42.2) | 126 (31.7) | 195 (53.7) | |
a
For HPV-uninfected participants and participants with prevalent HPV, baseline was defined as POPS enrollment. For participants with incident HPV, baseline was defined as visit of incident HPV detection.